Waters Corporation
$ 355.44
-0.44%
18 Jun - close price
- Market Cap 34,899,182,000 USD
- Current Price $ 355.44
- High / Low $ 360.65 / 353.56
- Stock P/E 45.22
- Book Value 155.78
- EPS 7.86
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.05 %
- 52 Week High 414.15
- 52 Week Low 275.05
About
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Analyst Target Price
$400.27
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-09 | 2025-11-04 | 2025-08-04 | 2025-05-06 | 2025-02-12 | 2024-11-01 | 2024-07-31 | 2024-05-07 | 2024-02-06 | 2023-11-07 | 2023-08-02 |
| Reported EPS | 2.7 | 4.53 | 3.4 | 2.95 | 2.25 | 4.1 | 2.93 | 2.63 | 2.21 | 3.62 | 2.84 | 2.8 |
| Estimated EPS | 2.31 | 4.51 | 3.22 | 2.94 | 2.22 | 4.03 | 2.68 | 2.56 | 2.09 | 3.55 | 2.55 | 2.59 |
| Surprise | 0.39 | 0.02 | 0.18 | 0.01 | 0.03 | 0.07 | 0.25 | 0.07 | 0.12 | 0.07 | 0.29 | 0.21 |
| Surprise Percentage | 16.8831% | 0.4435% | 5.5901% | 0.3401% | 1.3514% | 1.737% | 9.3284% | 2.7344% | 5.7416% | 1.9718% | 11.3725% | 8.1081% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 3.0 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WAT
2026-06-21 05:51:10
This article provides a background on Waters Corp (WAT), a lab-analytics specialist, on a Sunday with no new corporate headlines. It details how the company generates revenue from high-performance liquid chromatography and mass spectrometry systems, highlighting strong demand in pharmaceuticals and life sciences. The report also notes HSBC's raised price target and the company's solid Q1 2026 earnings, emphasizing the stability provided by recurring revenue from services and consumables.
2026-06-19 21:29:01
This article discusses Waters Corporation's stock performance and analyst consensus after its strong Q1 2026 earnings beat. The company raised its full-year guidance, leading to an overall "Buy" consensus among analysts with an average price target of $404.24. The article also compares Waters to its peers, Thermo Fisher Scientific and Agilent Technologies, highlighting its specialization in high-performance liquid chromatography and mass spectrometry.
2026-06-19 03:36:57
This article reviews the Q1 results for several research tools & consumables stocks, highlighting Agilent (A) as a benchmark. It discusses the sector's dynamics, including its reliance on recurring revenue and exposure to research and clinical markets, while also noting challenges like high R&D costs and pricing pressures. The report details the performance of Agilent, Waters Corporation (WAT), Revvity (RVTY), Thermo Fisher (TMO), and Bruker (BRKR), noting Waters Corporation had the best Q1 and Revvity the slowest.
2026-06-18 17:11:12
Waters Corp (WAT) stock remains a focus for investors following strong Q1 2026 earnings, raised guidance, and a consolidation near recent highs. The company, which specializes in analytical instruments for laboratories, saw robust demand across pharma and industrial sectors. Analysts project moderate upside, with HSBC raising its price target on the stock.
2026-06-18 15:10:57
The article provides an earnings forecast for Waters Corp (WAT), highlighting its current earnings forecast score of 7.67, ranking 128 out of 204 in its industry. Analysts set an average price target of $395.00, with a consensus leaning towards a "Buy" rating based on 25 analysts. The report also details expected revenue for the next quarter at $1.62 billion and provides recent and forecasted EPS figures.
2026-06-18 12:56:41
A new study by Hackensack Meridian CDI and Quest Diagnostics, published in Nature Communications, reveals that a common bacterial strain, Klebsiella pneumoniae, which causes UTIs, pneumonia, and wound infections, is showing high rates of multidrug resistance. The research, based on over 2,000 U.S. samples, found that 100% of the bacteria were multidrug-resistant and 69.5% were non-susceptible to three widely used oral antibiotics. This poses a significant public health concern, especially for older women, and highlights the urgent need for new treatment options and continued surveillance.
